Clearly, GMP showed capacity in fighting OxS in the circulation (MDA and F2 isoprostanes) and liver (GPx1), and in alleviating liver inflammation, which is documented by a decline in inflammatory biomarkers (COX-2, TNF-α and IL-6). The gene discussed is IL6; the disease is inflammatory response.